IP Library Granted Patent US 7,846,667
Granted Patent B2
US 7,846,667 · App. 12/545,028 · Granted Dec 7, 2010

Methods for the diagnosis and treatment of lung cancer

Assignees: Genzyme Corporation; Johns Hopkins University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,846,667
App. No.
12/545,028
Granted
Dec 7, 2010
Kind
B2
Abstract

The present invention provides methods for aiding in the diagnoses of the neoplastic condition of a lung cell and methods of screening for a potential therapeutic agent for the reversal of the neoplastic condition.

Claims (19)

1. A method for detecting and diagnosing lung cancer in a human patient, said method comprising:

(a) detecting the presence of an overexpressed b-mvb proto-oncogene in a lung cell sample taken from the patient; and

(b) determining that there is an indication of the presence of lung cancer in the patient when the proto-oncogene is overexpressed.

2. A method for identifying a human patient having lung cancer, said method comprising:

(a) determining the expression level of the b-myb proto-oncogene in a lung cell sample isolated from the patient; and

(b) identifying the patient as likely to have lung cancer when the expression level of the proto-oncogene in the sample is above the level of expression of the proto-oncogene in normal lung cells.

3. The method of claim 1 or 2 , further comprising:

(a) determining the expression level of the PGP9.5 proto-oncogene in a lung cell sample isolated from the patient; and

(b) determining that there is a further indication of the presence of lung cancer in the patient when the PGP9.5 proto-oncogene is overexpressed.

4. The method of claim 2 , wherein determining the expression level of the b-myb proto-oncogene comprises measuring the quantity of mRNA transcribed from the b-myb proto-oncogene in the sample.

5. The method of claim 2 , wherein determining the expression level of the b-myb proto-oncogene comprises measuring the quantity of cDNA produced from the reverse transcription of the b-myb mRNA in the sample.

6. The method of claim 2 , wherein determining the expression level of the b-myb proto-oncogene comprises measuring the quantity of the polypeptide or protein encoded by the b-myb proto-oncogene in the sample.

7. The method of claim 1 or 2 , wherein the lung cancer is non-small cell lung cancer.

8. The method of claim 2 , wherein determining the expression level of the b-myb proto-oncogene comprises probing the lung cell sample with a probe or primer comprising the sequence TGCTGCCCTG (SEQ. ID No. 1) or its complement.

9. The method of claim 1 , wherein detecting the presence of an overexpressed b-mvb proto-oncogene in a lung cell sample taken from the patient comprises measuring the quantity of mRNA transcribed from the b-myb proto-oncogene in the sample.

10. The method of claim 1 , wherein detecting the presence of an overexpressed b-mvb proto-oncogene in a lung cell sample taken from the patient comprises measuring the quantity of mRNA transcribed from the b-myb proto-oncogene in the sample.

11. The method of claim 1 , wherein detecting the presence of an overexpressed b-mvb proto-oncogene in a lung cell sample taken from the patient comprises measuring the quantity of cDNA produced from the reverse transcription of the b-myb mRNA in the sample.

12. The method of claim 1 , wherein detecting the presence of an overexpressed b-mvb proto-oncogene in a lung cell sample taken from the patient comprises measuring the quantity of the polypeptide or protein encoded by the b-myb proto-oncogene in the sample.

13. The method of claim 1 , wherein detecting the presence of an overexpressed b-mvb proto-oncogene in a lung cell sample taken from the patient comprises probing the lung cell sample with a probe or primer comprising the sequence TGCTGCCCTG (SEQ. ID No. 1) or its complement.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2011
From: JEN, JIN; SIDRANSKY, DAVID
To: JOHN HOPKINS UNIVERSITY SCHOOL OF MEDICINE
Reel/Frame 025966/0161 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2011
From: BEAUDRY, GARY A.; MADDEN, STEPHEN L.; BERTLESEN, ARTHUR H.
To: GENZYME CORPORATION
Reel/Frame 025966/0259 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2011
From: GENZYME CORPORATION
To: ESOTERIX GENETIC LABORATORIES, LLC
Reel/Frame 025656/0581 →
Continuity (4)
Division 1150426000 · Aug 14, 2006
Continuation 0964647800
Provisional Application 6008004400 · Mar 31, 1998
Related Publication 20100062443A1 · Mar 11, 2010